An observational study in Acromegaly, sponsored by Ipsen. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-17.
Sponsored by Ipsen · Observational
The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.
196 studies on the registry are indexed under Acromegaly; 18 are open to participants now.
Browse Acromegaly studies →Ipsen is the lead sponsor of 282 studies on the registry; 16 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
For Patients:
For Physicians:
Exclusion Criteria:
Overall patient satisfaction with SSA treatment.
To be assessed by four levels of satisfaction including very satisfied, satisfied, dissatisfied, and very dissatisfied
Time frame: During the whole study period (approximately 3 months).
Patient satisfaction with symptom control of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Patient satisfaction with frequency of administration of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Patient satisfaction with mode of administration of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Patient satisfaction with convenience of administration of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Patient satisfaction with injection site reactions of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Patient satisfaction with adverse reactions to SSA treatment
Time frame: During the whole study period (approximately 3 months).
Physician overall satisfaction with SSA treatment.
The satisfaction rate is calculated as the proportion of physicians who reported to be satisfied or very satisfied with the prescribed SSA treatment.
Time frame: During the whole study period (approximately 3 months).
Physician satisfaction with symptom control of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Physician satisfaction with frequency of administration of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Physician satisfaction with mode of administration of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Physician satisfaction with convenience of administration of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Physician satisfaction with injection site reactions of SSA treatment
Time frame: During the whole study period (approximately 3 months).
Physician satisfaction with adverse reactions to SSA treatment
Time frame: During the whole study period (approximately 3 months).
Aspects of patient concern before initiating SSA treatment
The magnitude of concern will be assessed by four levels including not concerned, slightly concerned, concerned, and very concerned.
Time frame: During the whole study period (approximately 3 months).
Aspects of physician concern before prescribing SSA treatment
The magnitude of concern will be assessed by four levels including not concerned, slightly concerned, concerned, and very concerned.
Time frame: During the whole study period (approximately 3 months).
Overall patient satisfaction with SSA treatment: satisfied versus dissatisfied with their SSA treatment.
The patient satisfaction will be categorized as binary variables including satisfied (very satisfied and satisfied) versus dissatisfied (dissatisfied and very dissatisfied).
Time frame: During the whole study period (approximately 3 months).
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
No publications or documents are linked to this record.
This study is withdrawn, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ipsen